If you weren’t paying attention — and most people outside of the biotech industry weren’t — the Cambridge company’s shares went nowhere after its initial public offering in late 2018.
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.